Drugs and Orthodontic Treatment

PART 2

Creating Brighter Futures
PART 1 reviewed the effects of Non-Steroidal Anti-Inflammatory drugs as well as Corticosteroids on orthodontic tooth movement (OTM) through their role as mediators in bone metabolism.

PART 2 will review a range of relevant medications and dietary supplements.

**Anti-convulsants**
Seizure disorders are characterised by sudden involuntary time-limited alterations in neurologic function resulting from abnormal electrical discharge of cerebral neurons. The treatment of these conditions involves polypharmacy with multiple anti-convulsant medications. The drugs which are important to orthodontic treatment are Valproic acid, Phenytoin and Gabapentin.

Valproic acid has the potential to induce gingival bleeding and Phenytoin induces gingival hyperplasia making application of orthodontic mechanics and oral hygiene practices more difficult. Gingival hyperplasia has also been reported with sodium valproate and ethosuximide. Gabapentin produces xerostomia which compromises oral hygiene.

**Calcium and calcium regulators**
Calcium plays a very important role in tooth movement and bone remodelling. Calcium homeostasis is regulated not only by dietary intake but by hormones such as Parathyroid Hormones, Thyroid Hormones (Thyroxin, Calcitonin), Sex Hormones (oestrogens) and Vitamins (Vitamin D3).

**Parathyroid Hormone (PTH)**
This hormone is secreted by the parathyroid gland. It increases the concentration of calcium in blood which stimulates bone resorption. Pathologic conditions of this gland will result in Hypoparathyroidism or Hyperparathyroidism.

<table>
<thead>
<tr>
<th>PATHOLOGY</th>
<th>DEFINITION</th>
<th>TREATMENT</th>
<th>EFFECT ON OTM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoparathyroidism</td>
<td>Lack of active PTH</td>
<td>• Vitamin D</td>
<td>Inhibits bone resorption</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Calcium Supplementation</td>
<td></td>
</tr>
<tr>
<td>Primary Hyperparathyroidism</td>
<td>Overproduction of PTH</td>
<td>• Surgical removal of the gland</td>
<td>Stimulates bone resorption</td>
</tr>
<tr>
<td></td>
<td>PTH which results in high serum Ca+ levels</td>
<td>• Medication with Bisphosphonates</td>
<td></td>
</tr>
<tr>
<td>Secondary Hyperparathyroidism</td>
<td>Hypocalcaemia increases production of PTH</td>
<td>• Vitamin D supplementation</td>
<td>Stimulates bone resorption</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Phosphate binders</td>
<td></td>
</tr>
</tbody>
</table>

TABLE 1 Continuous elevation of PTH leads to bone loss but intermittent short elevations of this hormone can be anabolic for bone, increasing mass, density and strength. OTM is stimulated by PTH in a dose-dependent manner.
Thyroid Hormones
Thyroid hormones are able to promote bone maturation and resorption. They directly stimulate osteoclastic activity and also have an indirect effect through insulin-like growth factor.

Thyroxin (T4) affects intestinal calcium absorption and is indirectly involved in bone turnover. Therefore, hyperthyroidism or thyroxin medication can lead to osteoporosis. L-Thyroxin has been recommended to reduce root resorption because it increases the resistance of cementum and dentine to clastic activity.23,24 Exogenous thyroxin has been shown to increase the rate of OTM in rats, on a dose dependant basis, resulting in reduction of the extent of root resorption.25 Clinical applications of these drugs still need to be clarified.

Calcitonin hormone is used to treat postmenopausal osteoporosis, hypercalcaemia, and Paget’s disease. Although this hormone is related to bone remodelling and calcium homeostasis, no experimental data are available on its effect on OTM.

Oestrogens
Oestrogens inhibit the production of cytokines involved in osteoclast activation and bone resorption.26 Decreased oestrogens after menopause are linked to the development of osteoporosis. Currently, osteoporosis is being treated with a specific oestrogen receptor modulator (Raloxifene), which has an oestrogenic effect on bone. Research found that the rate of OTM was inversely related to oestrogen serum level.27,28 Therefore oestrogen supplementation might slow OTM however there are no experimental studies on exogenous oestrogens and their effect on OTM.

Vitamin D3 (1,25 dihydroxycholecalciferol)
Vitamin D promotes absorption of calcium and phosphate thereby regulating their serum concentration levels. It also promotes bone deposition, inhibits PTH release and promotes immunosuppression. Its deficiency may result from inadequate intake combined with insufficient sunlight exposure, eventually leading to impaired bone mineralization, rickets and osteoporosis. In addition, it can also lead to increased susceptibility to high blood pressure, periodontal disease, affective disorders and auto-immune diseases. Therapy for its deficiency involves dietary changes or taking vitamin D3 supplements.

Experiments on rats have shown that Vitamin D3 stimulates the rate of OTM in a dose dependent manner.21,22 Physiologic doses do not stimulate bone resorption, however low supplemental administration does, possibly by stimulating osteoclast differentiation.23 This effect could help stabilize orthodontic movement. Investigations have suggested that local application of vitamin D could facilitate regeneration of supporting tissue, particularly alveolar bone, after orthodontic treatment.24,25

Dietary calcium
Calcium is often prescribed as a dietary supplement for the prevention of osteoporosis in postmenopausal women. Experiments on animals have shown that a low calcium diet leads to a higher rate of OTM compared to a high calcium diet26 and a control group.27 There is also an increase in the number of osteoclasts and osteoblasts in rats with low calcium diet and therefore an increase in bone remodelling, where excessive bone resorption prevails over deposition.28

Bisphosphonates
This class of pharmacological agents selectively inhibits osteoclasts. They are used to treat and prevent metabolic bone diseases associated with excessive bone resorption such as osteoporosis, Paget’s disease, bone metastases, and bone pain from some types of cancer.29 These drugs are incorporated in the bone matrix and have an extremely long half-life of about 10 years or more. Bisphosphonates can therefore affect bone metabolism for many years after the patient has completed therapy.

Long-term use of bisphosphonates may cause osteonecrosis, especially in the alveolar bone of the maxilla and the mandible.30 Studies show a dose-dependent decrease in the rate of OTM following topical or systemic administration. Furthermore, it has resulted in reduced root resorption when used without a nitrogen atom (Clodronate).31,32 Topical applications of bisphosphonate have been suggested as being useful in orthodontic anchorage and retention.33 However it has also been reported that these drugs produce cementum surface alterations by inhibiting acellular cementum formation, thereby actually increasing vulnerability to root resorption.1

Further studies are required before these drugs can be used in clinical orthodontic therapy.

<table>
<thead>
<tr>
<th>Systemic Factor</th>
<th>Effect on bone metabolism movement</th>
<th>Effect on tooth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oestrogen</td>
<td>↓ Bone resorption</td>
<td>↓ Tooth movement</td>
</tr>
<tr>
<td>Thyroid hormones</td>
<td>↑ Rate of bone remodelling and bone resorption</td>
<td>↑ Tooth movement</td>
</tr>
<tr>
<td>Parathyroid hormones</td>
<td>↑ Bone resorption</td>
<td>↑ Tooth movement</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>↑ Rate of bone remodelling and bone resorption</td>
<td>↑ Tooth movement</td>
</tr>
</tbody>
</table>

| FIGURE 1 |

| TABLE 2 |

**Psychiatric medication**
Orthodontic patients may suffer from psychiatric disorders such as attention-deficit / hyperactivity disorder, depression, eating disorder, and anxiety amongst others. Attention deficit / hyperactivity disorder is principally treated by central nervous system stimulants (Methylphenidate, dextroamphetamine, atomoxetine, etc) which may affect compliance and oral hygiene.35 Patients medicated with anti-depressants and mood stabilizers could present being overly concerned about their appearance while simultaneously being non-compliant. Benzodiazepines are often used for those suffering anxiety disorder or psychological stress. These patients may be more concerned about side effects and outcomes, but will utilize every chance to disrupt office visits.

**EFFECT OF SYSTEMIC FACTORS ON INDUCED TOOTH MOVEMENT**

<table>
<thead>
<tr>
<th>Systemic Factor</th>
<th>Effect on bone metabolism movement</th>
<th>Effect on tooth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oestrogen</td>
<td>↓ Bone resorption</td>
<td>↓ Tooth movement</td>
</tr>
<tr>
<td>Thyroid hormones</td>
<td>↑ Rate of bone remodelling and bone resorption</td>
<td>↑ Tooth movement</td>
</tr>
<tr>
<td>Parathyroid hormones</td>
<td>↑ Bone resorption</td>
<td>↑ Tooth movement</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>↑ Rate of bone remodelling and bone resorption</td>
<td>↑ Tooth movement</td>
</tr>
</tbody>
</table>

**Psychiatric medication**
Orthodontic patients may suffer from psychiatric disorders such as attention-deficit / hyperactivity disorder, depression, eating disorder, and anxiety amongst others. Attention deficit / hyperactivity disorder is principally treated by central nervous system stimulants (Methylphenidate, dextroamphetamine, atomoxetine, etc) which may affect compliance and oral hygiene.35 Patients medicated with anti-depressants and mood stabilizers could present being overly concerned about their appearance while simultaneously being non-compliant. Benzodiazepines are often used for those suffering anxiety disorder or psychological stress. These patients may be more concerned about side effects and outcomes, but will utilize every chance to disrupt office visits.
Brighter Futures is published by the Australian Society of Orthodontists (NSW Branch) Inc. in conjunction with the Orthodontic Discipline at the University of Sydney.

The newsletter is intended to help keep the dental profession updated about contemporary orthodontics, and also to help foster co-operation within the dental team.

Without the generous support of Henry Schein Halas and Colgate, who are an integral part of the dental team, this publication would not be possible.

The statements made and opinions expressed in this publication are those of the authors and are not official policy of, and do not imply endorsement by, the ASO (NSW Branch) Inc or the Sponsors.

Correspondence is welcome and should be sent to:

Department of Orthodontics
University of Sydney
Sydney Dental Hospital
2 Chalmers Street,
Surry Hills NSW 2010

AUTHOR & EDITORS

Dr Angie Phelan
Dr Vanessa Jimenez
Prof M Ali Darendeliler
Dr Dan Vickers
Dr Michael Dineen
Dr Ross Adams
Dr Nour Eldin Tarraf
Ms Lenore Tuckerman

www.aso.org.au

Conclusion

Current orthodontic research aims to develop methods of increasing the tissue concentration of molecules promoting tooth movement, while simultaneously decreasing the concentration of unwanted elements which can produce harmful side effects.14

Researchers have injected prostaglandins locally at the site of orthodontic tooth movement to enhance the bone remodelling process and the pace of tooth movement. The main side effect associated with local injection of prostaglandins is hyperalgesia due to the release of noxious agents. Recent trends are directed toward combining local anaesthetics with prostaglandins to reduce pain when locally injected.

Certain drugs that inhibit tooth movement are being investigated for use in supplementing anchorage and prevention of relapse. Local injection of echistatin and RGD peptides has been trialled in rats to prevent tooth movement thereby enhancing anchorage.14 While many substances show promise for enhancing orthodontic therapy, the clinician must be aware of the potentially adverse effects of medications that patients may be taking if unfavourable side effects are to be avoided. Bisphosphonate therapy or vitamin supplements may be crucial. The value of a thorough medical history is increasingly significant as young and old alike are exposed to a greater range of therapeutic agents.

REFERENCES AVAILABLE ON REQUEST

<table>
<thead>
<tr>
<th>Drug</th>
<th>Effect on bone metabolism</th>
<th>Effect on tooth movement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-steroidal anti-inflammatory drugs</td>
<td>Bone resorption</td>
<td>Tooth movement</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Bone resorption (CHRONIC USE)</td>
<td>Tooth movement</td>
</tr>
<tr>
<td>Bisphosphonates</td>
<td>Bone resorption</td>
<td>Tooth movement</td>
</tr>
<tr>
<td>Acetaminophen</td>
<td>Unproven</td>
<td>No influence</td>
</tr>
</tbody>
</table>

TABLE 3

For enquiries or to order the webcast contact: program@icms.com.au

Webcasting of Congress Lectures

The International Orthodontic Congress is only held once every 5 years and brings together the very best lecturers, researchers and clinicians from all around the world.

Most lectures in the Doctors’ Scientific Program have been recorded and are available via webcast. The comprehensive congress program can be viewed on www.wfosydney.com/griddoctor.asp

Webcast viewing of all recorded lectures can be purchased, until June 30th 2010, for $375. You will be able to view the webcasts, as often as you like and at any time, until February 2012.

For enquiries or to order the webcast contact: program@icms.com.au

7th International Orthodontic Congress
Sydney | Australia | 6 – 9 February 2010
Incorporating the 7th Asian Pacific Orthodontic Conference and the 4th Australasian Orthodontic Congress

Your Dental One Stop Shop!